NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 292.56 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.42
▲ +0.11 (4.76%)

This chart shows the closing price for RIGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rigel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RIGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RIGL

Analyst Price Target is $9.50
▲ +292.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Rigel Pharmaceuticals in the last 3 months. The average price target is $9.50, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 292.56% upside from the last price of $2.42.

This chart shows the closing price for RIGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Rigel Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2021BMO Capital MarketsReiterated RatingBuy$8.00Low
9/28/2021HC WainwrightReiterated RatingBuy$11.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$11.00Low
3/11/2021HC WainwrightReiterated RatingBuy$11.00Medium
2/18/2021HC WainwrightBoost Price TargetBuy$8.00 ➝ $11.00High
11/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
8/6/2020CitigroupBoost Price TargetBuy$7.00 ➝ $8.00High
7/9/2020HC WainwrightReiterated RatingBuy$8.00Medium
5/27/2020JPMorgan Chase & Co.Lower Price TargetOverweight$7.00 ➝ $6.00Low
12/18/2019HC WainwrightReiterated RatingBuy$8.00Low
12/9/2019BMO Capital MarketsLower Price TargetOutperform$11.00 ➝ $8.00Low
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
9/26/2019JPMorgan Chase & Co.Reiterated RatingOverweight$7.00High
9/23/2019HC WainwrightSet Price TargetBuy$8.00High
5/7/2019Cantor FitzgeraldReiterated RatingBuy$7.00High
2/28/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$9.00 ➝ $7.00Medium
1/23/2019HC WainwrightReiterated RatingBuy$8.00Medium
1/23/2019Cantor FitzgeraldReiterated RatingBuy$9.00High
1/11/2019HC WainwrightSet Price TargetBuy$8.00Low
1/8/2019Cantor FitzgeraldReiterated RatingBuy$9.00Low
12/4/2018HC WainwrightSet Price TargetBuy$8.00High
12/3/2018Cantor FitzgeraldSet Price TargetBuy$9.00High
11/7/2018HC WainwrightSet Price TargetBuy$8.00High
10/29/2018HC WainwrightSet Price TargetBuy$8.00High
10/29/2018Cantor FitzgeraldSet Price TargetBuy$9.00High
10/11/2018HC WainwrightSet Price TargetBuy$8.00Low
10/5/2018HC WainwrightSet Price TargetBuy$8.00Medium
10/3/2018Cantor FitzgeraldReiterated RatingBuy$9.00Low
9/4/2018JPMorgan Chase & Co.Reiterated RatingOverweight$7.00Low
8/27/2018CitigroupInitiated CoverageBuy ➝ Buy$8.50High
8/9/2018HC WainwrightReiterated RatingBuy$8.00Low
8/8/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
5/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00High
5/2/2018HC WainwrightLower Price TargetBuy ➝ Buy$8.00 ➝ $7.50High
5/1/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Overweight$6.00 ➝ $9.00High
5/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$7.00 ➝ $8.00High
4/18/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $8.00High
4/18/2018Jefferies Financial GroupBoost Price TargetBuy$7.00High
4/18/2018HC WainwrightSet Price TargetBuy$8.00High
4/17/2018Cantor FitzgeraldSet Price TargetBuy$6.00High
4/17/2018Piper Jaffray CompaniesBoost Price TargetOverweight$6.00 ➝ $7.00High
4/3/2018HC WainwrightLower Price TargetBuy ➝ Buy$7.00 ➝ $6.70Medium
4/3/2018Cantor FitzgeraldReiterated RatingBuy$6.00High
3/7/2018HC WainwrightSet Price TargetBuy$7.00High
3/6/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
2/2/2018HC WainwrightReiterated RatingBuy$7.00Low
1/19/2018HC WainwrightSet Price TargetBuy$7.00High
12/21/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$6.00Low
12/14/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$6.00High
12/11/2017HC WainwrightSet Price TargetBuy$7.00High
11/6/2017HC WainwrightReiterated RatingBuy ➝ Buy$7.00N/A
10/4/2017Jefferies Financial GroupReiterated RatingBuy$5.00Medium
10/2/2017BMO Capital MarketsReiterated RatingBuy$5.00Low
9/5/2017Jefferies Financial GroupReiterated RatingBuy$5.00High
6/19/2017BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$4.00 ➝ $5.00Low
5/3/2017HC WainwrightReiterated RatingBuy$6.00Medium
3/9/2017HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $5.00Low
3/8/2017Jefferies Financial GroupReiterated RatingBuy$5.00High
3/8/2017BMO Capital MarketsReiterated RatingOutperform$4.00High
1/30/2017BMO Capital MarketsReiterated RatingOutperform$4.00N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Rigel Pharmaceuticals logo
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $2.42
Low: $2.27
High: $2.44

50 Day Range

MA: $2.70
Low: $2.31
High: $3.26

52 Week Range

Now: $2.42
Low: $2.27
High: $5.50

Volume

1,606,964 shs

Average Volume

1,625,310 shs

Market Capitalization

$413.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Rigel Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rigel Pharmaceuticals in the last twelve months: BMO Capital Markets, HC Wainwright, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for RIGL.

What is the current price target for Rigel Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Rigel Pharmaceuticals in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 292.6%. HC Wainwright has the highest price target set, predicting RIGL will reach $11.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $8.00 for Rigel Pharmaceuticals in the next year.
View the latest price targets for RIGL.

What is the current consensus analyst rating for Rigel Pharmaceuticals?

Rigel Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RIGL will outperform the market and that investors should add to their positions of Rigel Pharmaceuticals.
View the latest ratings for RIGL.

What other companies compete with Rigel Pharmaceuticals?

How do I contact Rigel Pharmaceuticals' investor relations team?

Rigel Pharmaceuticals' physical mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 624-1100 and its investor relations email address is [email protected] The official website for Rigel Pharmaceuticals is www.rigel.com.